Date: 2014-06-30
Type of information: Private placement
Company: Ablynx (Belgium)
Investors: domestic and international institutional investors
Amount: €41.7 million
Funding type: private placement
Planned used: The funds will be used to allow flexibility in the choices regarding further development of Ablynx\'s currently fully-owned clinical assets caplacizumab (anti-vWF) and ALX-0171 (anti-RSV); to continue to build momentum with Nanobodies® targeted to immune check-point inhibitors and accelerate the development of such assets both in wholly-owned programmes and with partners; to initiate, continue to advance, and/or accelerate the pre-clinical and clinical development of wholly- and co-owned programmes to further expand the Company\'s diverse portfolio of programme assets; and for general corporate purposes.
Others: * On June 30, 2014, Ablynx announced that it has raised €41,720,822 through a private placement of new shares via an accelerated book building procedure announced on 30 June 2014. The private placement has allowed Ablynx to place 4,908,332 new shares with domestic and international institutional investors at a price of €8.50 per share, a 5.56% discount to the previous day\'s closing price. The new shares represent 10% of the current number of outstanding shares and will bring the total number of shares after the issue to 53,991,659. The new shares will be admitted to trading on Euronext Brussels following their issuance, which is expected to take place on 3 July 2014. Jefferies International Limited, KBC Securities NV and Kempen & Co N.V. acted as Joint Bookrunners for the placement.
Therapeutic area: Cancer - Oncology - Hematological diseases - Inflammatory diseases - Lung diseases
